Skip to main content
TTrialFinder
TrialFinder is for informational purposes only and does not provide medical advice. Always talk to your doctor.

Acute Myeloid Leukemia Clinical Trials

107 recruiting trials for Acute Myeloid Leukemia. Eligibility criteria explained in plain English.

Important: This information is not medical advice. Talk to your doctor about whether a clinical trial is right for you.
107
Total Trials
107
Recruiting Now
5
Phase 3 Trials
10
Sponsors

Recruiting Trials

Clinical trial data sourced from the ClinicalTrials.gov registry, maintained by the National Library of Medicine. Always consult your doctor before considering any clinical trial.

RECRUITINGNCT05366881

cfDNA Assay Prospective Observational Validation for Early Cancer Detection and Minimal Residual Disease

This is an observational case-control study to train and validate a genome-wide methylome enrichment platform to detect multiple cancer types and to differentiate amongst cancer...

Sponsor: Adela, IncEnrolling: 700017 locations
RECRUITINGNCT03452774

SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry

International registry for cancer patients evaluating the feasibility and clinical utility of an Artificial Intelligence-based precision oncology clinical trial matching tool,...

Sponsor: Massive Bio, Inc.Enrolling: 5000020 locations
RECRUITINGPhase 4NCT06918054

Hepatoprotective for Children and Adolescent With Acute Lymphoblastic Leukemia

This current study will implement a proposed whole program of monitoring and prevention acute hepatic injury during the time of induction chemotherapy in children and adolescent...

Sponsor: Ain Shams UniversityEnrolling: 422 locations
RECRUITINGPhase 2NCT05417165

Anti-pneumococcal Vaccine Strategy in Patients With Chronic Lymphocytic Leukemia

This phase II trial compares the effect of initial vaccination (PCV20 followed by PSV23) with yearly vaccinations of PSV23 to the standard 5 year vaccination in patients with...

Sponsor: Seema BhatEnrolling: 801 location
RECRUITINGNCT07244367

Maintenance Venetoclax in AML Fit Patients

this study will explore the efficacy of maintenance SC cytarabine + venetoclax therapy as regard disease free survival (DFS) in AML fit patients who achieved CR after highly...

Sponsor: Sohag UniversityEnrolling: 802 locations
RECRUITINGPhase 1NCT05210907

Clinical Study of Hospital-manufactured CD19 CAR-T in Children and Adolescents With Acute Lymphoblastic Leukemia

Chimeric antigen receptor T cells (CAR-T cells) have been developed to treat relapsed and refractory hematological malignancies with promising outcome in patients with very poor...

Sponsor: Seoul National University HospitalEnrolling: 51 location
RECRUITINGPhase 1 / Phase 2NCT04195347

Study of CM4620 to Reduce the Severity of Pancreatitis Due to Asparaginase

This is a phase I/II clinical trial assessing the tolerability and efficacy of CM4620 in children and young adults with acute pancreatitis caused by asparaginase. The tolerability...

Sponsor: St. Jude Children's Research HospitalEnrolling: 422 locations
RECRUITINGNCT04841447

Membrane Target Detection for Leukemia Treatment

Acute myeloid leukemia (AML) accounts for more than 40% of leukemia mortality in the United States. Each year around ten thousand people die from the disease, most within a few...

Sponsor: University of Missouri-ColumbiaEnrolling: 501 location
RECRUITINGNCT05745285

Leukemia and Lymphoma Society (LLS) Services Impact on Outcomes and Care

The purpose of this study is to learn about the impact that the services and programs provided by Blood Cancer United (formerly, The Leukemia and Lymphoma Society) have among...

Sponsor: University of MiamiEnrolling: 4003 locations
RECRUITINGPhase 4NCT02670564

ALL SCTped FORUM - Pharmacogenomic Study (add-on Study)

Pharmacogenomics (PG) offers the opportunity to individualize treatment according to patient genetic variations which influence activity of enzyme metabolizing or acting in the...

Sponsor: Swiss Pediatric Oncology GroupEnrolling: 10004 locations
RECRUITINGNCT06065852

National Registry of Rare Kidney Diseases

The goal of this National Registry is to is to collect information from patients with rare kidney diseases, so that it that can be used for research. The purpose of this research...

Sponsor: UK Kidney AssociationEnrolling: 350001 location
RECRUITINGPhase 2NCT05736978

Adaptive Treatment for Acute Myeloid Leukemia Based on D14 MRD Results

This is a prospective, single-arm, multi-center clinical trial to evaluate the efficacy and safety of selinexor in combination with azacitidine and venetoclax for untreated acute...

Sponsor: Shanghai Tong Ren HospitalEnrolling: 584 locations
RECRUITINGNCT03466944

PUMA (Paediatric Osseous Marrow Assessment)

This is a pilot cancer imaging study investigating change in the apparent diffusion coefficient (ADC) at a single time point post-transplantation in patients. The treatment is...

Sponsor: Institute of Cancer Research, United KingdomEnrolling: 121 location
RECRUITINGPhase 2NCT06429098

Study of A Venetoclax-based, Anthracycline-free Regimen in Newly Diagnosed CBFβ::MYH11(+) AML

This investigator-initiated, single-arm, phase II trial is aimed to evaluate the efficacy and safety of a venetoclax-based, anthracycline-free regimen in patients with newly...

Sponsor: The First Affiliated Hospital of Soochow UniversityEnrolling: 402 locations
RECRUITINGPhase 1NCT03326921

HA-1 T TCR T Cell Immunotherapy for the Treatment of Patients With Relapsed or Refractory Acute Leukemia After Donor...

This phase I trial studies the side effects and best dose of CD4+ and CD8+ HA-1 T cell receptor (TCR) (HA-1 T TCR) T cells in treating patients with acute leukemia that persists,...

Sponsor: Fred Hutchinson Cancer CenterEnrolling: 241 location
RECRUITINGPhase 1 / Phase 2NCT06561152

Tagraxofusp and Low-Intensity Chemotherapy for CD123-Positive Relapsed or Refractory AML

To determine the efficacy of the combination of tagraxofusp, cladribine, and cytarabine.

Sponsor: Stanford UniversityEnrolling: 201 location
RECRUITINGPhase 1NCT03633955

Pilot Imaging Study of Leukemia

This is a prospective pilot study, the primary aim of which is to determine whether the presence of 18F FLT imaging signal uptake abnormalities correlate with clinically validated...

Sponsor: University of OklahomaEnrolling: 603 locations
RECRUITINGNCT05108298

Improving Adolescent and Young Adult Self-Reported Data in ECOG-ACRIN Trials

The purpose of this study is to evaluate feasibility and acceptability of completing PROs among AYAs randomized to Choice PRO vs Fixed PRO.

Sponsor: Eastern Cooperative Oncology GroupEnrolling: 40020 locations
RECRUITINGPhase 1NCT04659616

Pemigatinib After Chemotherapy for the Treatment of Newly Diagnosed Acute Myeloid Leukemia

This phase I trial identifies the best dose and clinical benefit of giving pemigatinib following standard induction chemotherapy in patients with newly diagnosed acute myeloid...

Sponsor: OHSU Knight Cancer InstituteEnrolling: 322 locations
RECRUITINGPhase 2NCT05672355

A Vaccine Booster (GEO-CM04S1) for the Prevention of COVID-19 in Patients With Chronic Lymphocytic Leukemia

This phase II trial compares the effect of the GEO-CM04S1 vaccine with the current standard of care vaccine in preventing COVID-19 infections in patients with chronic lymphocytic...

Sponsor: City of Hope Medical CenterEnrolling: 801 location
RECRUITINGNCT07499349

ESTABLISHMENT OF A PHARMACOKINETIC MODEL FOR ERWINASE PHARMACOKINETICS

The aim of this sub study is to optimize target trough attainment while minimizing high exposures that impose increased risk of side effects such as hyperammonemia. Clinical...

Sponsor: Aarhus University HospitalEnrolling: 4751 location
RECRUITINGPhase 3NCT04094311

Study of Out of Specification for Tisagenlecleucel

This study will evaluate the safety of tisagenlecleucel that is out of specification( OOS) for release as commercial product. Specifically, this study will evaluate the safety of...

Sponsor: Novartis PharmaceuticalsEnrolling: 20020 locations
RECRUITINGPhase 2NCT06059391

CMV-MVA Triplex Vaccination in HLA-Matched Related Stem Cell Donors for the Prevention of CMV Infection in Patients...

This phase II clinical trial tests how well the cytomegalovirus-modified vaccinica Ankara (CMV-MVA) Triplex vaccine given to human leukocyte antigens (HLA) matched related stem...

Sponsor: City of Hope Medical CenterEnrolling: 2163 locations
RECRUITINGNCT05691608

MoleculAr Profiling for Pediatric and Young Adult Cancer Treatment Stratification 2

FMG2025 continues the previous efforts to propose treatment for patients based on the molecular characteristics of their tumor at treatment failure in cancer precision medicine...

Sponsor: Gustave Roussy, Cancer Campus, Grand ParisEnrolling: 180020 locations
RECRUITINGPhase 1NCT05233618

Study of Tagraxofusp for Post-Transplant Maintenance for Patients With CD 123+ AML, MDS, MF and CMML (HSCT 002)

In this study, tagraxofusp (Tag) is given to patients with CD 123+ myelofibrosis (MF), chronic myelomonocytic leukemia (CMML), and acute myeloid leukemia (AML) after allogeneic...

Sponsor: Karen Ballen, MDEnrolling: 442 locations
RECRUITINGPhase 2NCT06716658

JAK1 Inhibitor Golidocitnib for the Treatment of Relapsed/Refractory Indolent T/NK-cell Lymphomas

Indolent T/NK-cell lymphomas are a heterogeneous group of lymphoproliferative diseases originating from T/NK cells, characterized by slow growth and proliferation, but currently...

Sponsor: Institute of Hematology & Blood Diseases Hospital, ChinaEnrolling: 482 locations
RECRUITINGNCT06116318

A Study of c-Kit Mutation as MRD in Acute Myeloid Leukemia

C-Kit is involved in an essential pathway of disease occurrence and is closely related to the poor prognosis of patients. However, the clinical significance of c-Kit mutation as...

Sponsor: Institute of Hematology & Blood Diseases Hospital, ChinaEnrolling: 501 location
RECRUITINGNCT06421155

Brain MRF in Children, Adolescents and Young Adults With Acute Leukemia

The survival of children, adolescents and young adults (AYA) with acute leukemia has improved dramatically over the last two decades. This success is a result of using multiple...

Sponsor: Case Comprehensive Cancer CenterEnrolling: 201 location
RECRUITINGEarly Phase 1NCT06514768

JY231 (JY231) Injection for the Treatment of B-cell Acute Lymphoblastic Leukemia (B-ALL)

Early exploratory clinical study of the safety, tolerability and initial efficacy of JY231 injection in the treatment of B-cell acute lymphoblastic leukemia (B-ALL)

Sponsor: 920th Hospital of Joint Logistics Support Force of People's Liberation Army of ChinaEnrolling: 201 location
RECRUITINGNCT06450145

Evaluate the Efficacy and Safety of Interferon-α Combined With ATO in the Treatment of Arsenic-resistant APL

This study was a single-arm, open study. After the screening period, arsenic-resistant APL patients were treated with interferon α-2b, arsenic and venetoclax. The efficacy (ORR)...

Sponsor: Zhejiang Provincial People's HospitalEnrolling: 152 locations
RECRUITINGEarly Phase 1NCT07312630

Clinical Study of LV009 Injection for the Treatment of Relapsed/Refractory CD19-Positive Hematologic and Lymphoid...

Evaluate the safety, pharmacokinetic (PK) characteristics, and pharmacodynamic (PD) characteristics of LV009 injection in subjects with relapsed/refractory CD19-positive...

Sponsor: PersonGen BioTherapeutics (Suzhou) Co., Ltd.Enrolling: 191 location
RECRUITINGPhase 2 / Phase 3NCT07366801

Co-infusion of Treg-enriched Donor Lymphocytes With CD3-depleted Hematopoietic Stem Cell Graft to Prevent Graft-versus...

Two key methods of GVHD prevention in allogeneic HSCT have a number of limitations: ex vivo T depletion is associated with an excess of infectious complications, and...

Sponsor: Federal Research Institute of Pediatric Hematology, Oncology and ImmunologyEnrolling: 641 location
RECRUITINGNCT04575883

HIIT in Youth With Congenital Heart Disease (MedBIKE)

Congenital heart disease (CHD), the most common birth defect, is present in nearly 1% of the population. CHD patients are associated with intense resource utilization and...

Sponsor: University of AlbertaEnrolling: 441 location
RECRUITINGPhase 2NCT05082519

Caloric Restriction and Activity to Reduce Chemoresistance in B-ALL

This study is for older children, adolescents, and young adults with B-cell Acute Lymphoblastic Leukemia (B-ALL). Higher amounts of body fat is associated with resistance to...

Sponsor: Etan OrgelEnrolling: 24020 locations
RECRUITINGNCT05626400

Clinical Study of Senl-T7 CAR T Cells in the Treatment of Relapsed and Refractory CD7+ Acute T-ALL/T-LBL

This is an open, prospective, dose-escalation clinical study to evaluate the safety and efficacy of Senl-T7 in patients with relapsed or refractory CD7+ acute T lymphoblastic...

Sponsor: Hebei Senlang Biotechnology Inc., Ltd.Enrolling: 1001 location
RECRUITINGPhase 2NCT04187105

BMT-06: Study of Intensity Modulated Total Marrow Irradiation (IM-TMI)

This study is being done to see if the addition of a targeted form of radiation to standard conditioning regimen will increase the amount of cancer cells that are killed off in...

Sponsor: University of Illinois at ChicagoEnrolling: 271 location
RECRUITINGPhase 4NCT06035757

The Occurrence of Emergence Agitation in Pediatric Strabismus Surgery

The present trial conducted to demonstrate the administration of sugammadex as reversal of neuromuscular blockade agent reduces the incidence of emergence agitation (EA) comparing...

Sponsor: Konkuk University Medical CenterEnrolling: 761 location
RECRUITINGPhase 1NCT05983965

Study of Tazemetostat in Lymphoid Malignancies

Tazemetostat is an oral EZH2 inhibitor which has been FDA approved for adult patients with relapsed or refractory (R/R) follicular lymphoma (FL) whose tumors are positive for an...

Sponsor: University of Alabama at BirminghamEnrolling: 301 location
RECRUITINGNCT05909501

Assessment of Geriatric Evaluations Impact on New AML Guidance

The goal of the study is to measure physiologic age (there is no current formal definition but is meant to imply that patients should be evaluated holistically rather than on age...

Sponsor: Abramson Cancer Center at Penn MedicineEnrolling: 1001 location
RECRUITINGNCT06237192

MRD-associated Non-intensive But Non-interruptive Treatment of Ph-negative Acute Lymphoblastic Leukemia Adult Patients

Non-intensive But Non-interruptive Treatment based on previously study RALL-2016 of Adult Ph-negative Acute Lymphoblastic Leukemia: No high-dose methotrexate (MTX) and high-dose...

Sponsor: National Research Center for Hematology, RussiaEnrolling: 2001 location
RECRUITINGPhase 3NCT06846671

A Study of BGB-16673 Compared to Investigator's Choice in Participants With Chronic Lymphocytic Leukemia or Small...

The purpose of this study is to investigate the efficacy and safety of BGB-16673 compared with investigator's choice (idelalisib plus rituximab \[for CLL only\] or bendamustine...

Sponsor: BeOne MedicinesEnrolling: 25020 locations
RECRUITINGPhase 1 / Phase 2NCT07109219

Study of AZD4512 Monotherapy or in Combination With Anticancer Agents in Participants With Acute Lymphoblastic Leukemia

The study is intended to assess the safety, tolerability, pharmacokinetics, pharmacodynamics, and efficacy of AZD4512 in patients with relapsed/refractory B-Cell acute...

Sponsor: AstraZenecaEnrolling: 8320 locations
RECRUITINGNCT07052916

A Music Therapy Study for Blood Cancer Survivors With Cognitive Difficulties

Research has shown that music-based activities may help improve brain functions, such as attention, memory, and executive function. Because of this past research, the researchers...

Sponsor: Memorial Sloan Kettering Cancer CenterEnrolling: 607 locations
RECRUITINGNCT01137643

Tissue, Blood, and Body Fluid Sample Collection From Patients With Hematologic Cancer

RATIONALE: Collecting and storing samples of tissue, blood, and body fluid from patients with cancer to study in the laboratory may help the study of cancer in the future....

Sponsor: UNC Lineberger Comprehensive Cancer CenterEnrolling: 150001 location
RECRUITINGPhase 1NCT06810583

A Prospective Trial of Dalbavancin-Based Prophylaxis in Children and Adolescents With High-Risk Leukemia

This is a single-arm pilot clinical trial evaluating dalbavancin-based prophylaxis in children and adolescents with acute myeloid leukemia or relapsed lymphoblastic leukemia...

Sponsor: St. Jude Children's Research HospitalEnrolling: 291 location
RECRUITINGEarly Phase 1NCT04227015

A Study of CTA101 UCAR-T Cell Injection in Patients With Relapsed or Refractory CD19+ B-line Hematological Malignancy

A study of CTA101 UCAR-T cell injection in patients with relapsed or refractory CD19+ B-line hematological malignancy

Sponsor: He HuangEnrolling: 721 location
RECRUITINGNCT05643235

Implanted Loop Recorders for Detection and Management of Arrhythmia With Bruton Tyrosine Kinase Inhibitors

This study will enroll patients initiating Bruton Tyrosine Kinase (BTK) inhibitors without history of documented arrhythmia while on therapy using the Medtronic LINQ-2 insertable...

Sponsor: Northwell HealthEnrolling: 501 location
RECRUITINGPhase 2NCT06561360

A Study of Vemurafenib and Obinutuzumab Compared to Cladribine and Rituximab in People With Hairy Cell Leukemia (HCL)

The researchers are doing this study to compare the safety of vemurafenib in combination with obinutuzumab to the standard of approach of cladribine in combination with rituximab....

Sponsor: Memorial Sloan Kettering Cancer CenterEnrolling: 8610 locations
RECRUITINGPhase 1 / Phase 2NCT06911710

The Application of CAR-T Cell Therapy in Relapsed and Refractory Malignant Hematologic Tumors

This study is an open, single-arm, prospective, Phase I/II clinical study using "3+3" dose escalation and dose expansion to investigate the safety, maximum tolerated dose, in vivo...

Sponsor: Tianjin Medical University General HospitalEnrolling: 901 location
RECRUITINGPhase 1NCT03326310

Selumetinib and Azacitidine in High Risk Chronic Blood Cancers

This is a phase I, open-label, dose-escalation study to determine the MTD of selumetinib when combined with the standard dose of azacitidine. Treatment will begin within 28 days...

Sponsor: University of ChicagoEnrolling: 181 location

Showing 50 of 107 trials.Search all Acute Myeloid Leukemia trials

Frequently Asked Questions

There are currently 107 clinical trials for Acute Myeloid Leukemia, with 107 actively recruiting participants. These include trials across all phases from early-stage Phase 1 to late-stage Phase 3.

To join a clinical trial for Acute Myeloid Leukemia, review the eligibility criteria on the trial detail pages, then talk to your doctor about whether a trial is right for you. Your doctor can help you evaluate the potential benefits and risks.

Phase 3 trials are large-scale studies that test whether a treatment is effective and monitor side effects. There are 5 Phase 3 trials for Acute Myeloid Leukemia, representing treatments closest to potential FDA approval.

Clinical trials follow strict safety protocols overseen by Institutional Review Boards (IRBs) and the FDA. Participants are monitored closely and can withdraw at any time. Always discuss risks and benefits with your healthcare provider before enrolling.

Sources: ClinicalTrials.gov, FDA
Last updated:

Trial data sourced from the ClinicalTrials.gov API. This site does not provide medical advice — always talk to your doctor about clinical trial participation.